摘要:
The invention refers to the use of O-(3-piperidino-2-hydroxypropyl)nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition increasing the mitochondrial genesis.
摘要:
O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce overweight or obesity and, preferably, reduce one or more unfavourable psychiatric side effects of the cannabinoid CB1 receptor antagonist.
摘要:
O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or the reduction of the rate of body weight.
摘要:
O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug.
摘要:
The invention refers to the use of an extract of a part of a Solidago species, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active agent for the preparation of a pharmaceutical composition suitable for the treatment of diabetic periodontitis.
摘要:
The invention relates to methods for prevention and/or treatment of skin lesions caused by exposure to ultraviolet radiation. Exemplary condition that can be prevented or treated are actinic keratosis, dry skin, polymorphic light exanthema, photopathology, photo-allergy, solar atrophy, stria migrans, elastoma diffusum, X-ray dermatitis, gouty polychondritis and decubitis ulcer. The method employs application to the skin of a composition comprising a hydroximic acid derivative of the formula
摘要:
The invention refers to pharmaceutical compositions suitable for the protection of the mitochondrial genom and/or mitochondrium from damages or for the treatment of diseases connected with such damages, said compositions comprising a hydroximic acid derivative of the formula: wherein R1 represents a hydrogen or a C1-5 alkyl group, R2 stands for a hydrogen, a C1-5 alkyl group, a C3-8 cycloalkyl group or a phenyl group optionally substituted by a hydroxy or a phenyl group, or R1 or R2 together with the nitrogen atom they are attached to form a 5 to 8 membered ring optionally containing one or more further nitrogen, oxygen or sulfur atom(s) and said ring can be condensed with another alicyclic or heterocyclic ring, preferably a benzene, naphthalene, quinoline, isoquinoline, pyridine or pyrazoline ring, furthermore, if desired and chemically possible, the nitrogen and/or sulfur heteroatom(s) are present in the form of an oxide or dioxide, R3 means a hydrogen, a phenyl group, a naphthyl group or a pyridyl group wherein said groups can be substituted by one or more halo atom(s) or C1-4 alkoxy group(s), Y is a hydrogen, a hydroxy group, a C1-24 alkoxy group optionally substituted by an amino group, a C2-24 polyalkenyl-oxy group containing 1 to 6 double bond(s), a C1-25 alkanoyl group, C3-9 alkenoyl group or a group of the formula R7—COO—, wherein R7 represents a C2-30 polyalkenyl group containing 1 to 6 double bond(s), X stands for a halo, an amino group, a C1-4 alkoxy group, or X forms with B an oxygen atom, or X and Y together with the carbon atoms they are attached to and the —NR—O—CH2 group being between said carbon atoms form a ring of the formula wherein Z represents an oxygen or a nitrogen, R stands for a hydrogen or R forms with B a chemical bond, A is a C1-4 alkylene group or a chemical bond or a group of the formula wherein R4 represents a hydrogen, a C1-5 alkyl group, a C3-8 cycloalkyl group or a phenyl group optionally substituted by a halo, a C1-4 alkoxy group or a C1-5 alkyl group, R5 stands for a hydrogen, a C1-4 alkyl group or a phenyl group, m has a value of 0, 1 or 2, n has a value of 0, 1 or 2, or a pharmaceutically acceptable acid addition salt thereof as the active ingredient.
摘要:
The invention refers to novel propenecarboxylic acid amidoxime derivatives furthermore N-oxides and/or geometrical isomers and/or optical isomers and/or pharmaceutically suitable acid addition salts and/or quaternary derivatives thereof. The novel compounds are suitable for the treatment of a state connected with oxygen deficit and/or energy deficit, or a disease based on PARP inhibition, especially an autoimmune or neurodegenerative disease, and/or a viral disease, and/or a disease caused by a toxic effect.
摘要:
The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The pharmaceutical combination is suitable for the prevention or treatment of, among others, diabetes mellitus.
摘要:
The invention concerns new compounds of the formula (I) ##STR1## wherein R.sup.1 is hydrogen, phenyl or phenyl substituted with at least one alkyl having 1 to 4 carbon atoms, halogen, alkoxy having 1 to 4 carbon atoms or nitro;R.sup.2 is alkyl having 1 to 4 carbon atoms, cycloalkyl having 5 to 7 carbon atoms, phenyl, or phenyl substituted with at least one alkyl having 1 to 4 carbon atoms, halogen, alkoxy having 1 to 4 carbon atoms or nitro;R.sup.3 is alkoxy having 1 to 4 carbon atoms or hydrogen,R.sup.4 is hydrogen, alkyl having 1 to 4 carbon atoms unsubstituted or substituted with alkoxy having 1 to 4 carbon atoms, benzyloxy or cyano, phenyl, or phenyl substituted with at least one alkyl having 1 to 4 carbon atoms, halogen, alkoxy having 1 to 4 carbon atoms or nitro, or phenyl-(C.sub.1-4 alkyl)-alkyl, in which the phenyl moiety may bear an alkoxy substituent having 1 to 4 carbon atoms or a halogen;m and n are each 0, 1 or 2 or a pharmaceutically acceptable acid addition or quaternary salt thereof.The compounds are potent vasodilators and exert a favorable influence on the extremital blood flow. They also show a heart function influencing activity.Methods for the preparation of said compounds and pharmaceutical compositions containing them are also the subject of the invention.